April 17 OncoMed Pharmaceuticals Inc
said on Monday its experimental drug failed a mid-stage study
for the treatment of lung cancer.
The trial was testing the combination of Oncomed's
tarextumab and chemotherapy, compared with chemotherapy and a
placebo. The main goal was to slow the progression of the
Last week, the company said it would discontinue a trial
testing its experimental drug, demcizumab, as an initial
treatment for advanced pancreatic cancer.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by